| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: 1 Departments of Pathology and Immunology, The Center for Cell and Gene Therapy; 2 Department of Pathology and 3 Scott Department of Urology, Baylor College of Medicine, Houston, Texas; and 4 Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York
Requests for reprints: Rong-Fu Wang, The Center for Cell and Gene Therapy, Baylor College of Medicine, ALKEK Building, N1120, One Baylor Plaza, Houston, TX 77030. Phone: 713-798-1244; Fax: 713-798-1263; E-mail: rongfuw{at}bcm.tmc.edu.
Purpose: Although elevated proportions of CD4+CD25+ regulatory T (Treg) cells have been shown in several types of cancers, very little is known about the existence and function of CD8+ Treg cells in prostate cancer. In this study, we investigated prostate tumor–derived CD8+ Treg cells and their function.
Experimental Design: Tumor-infiltrating lymphocytes (TIL) from fresh tumor specimens of patients with prostate cancer were generated and subjected to phenotypic and suppressive function analyses. In particular, we investigated the role and function CD8+ Treg cells in prostate cancer.
Results: We show that high percentages of CD4+CD25+ T cells are probably present in the majority (70%) of prostate TILs. Remarkably, both CD4+ and CD8+ T-cell subpopulations possessed potent suppressive activity. T-cell cloning and fluorescence-activated cell sorting analyses showed the presence of CD8+CD25+ Treg cell clones that expressed FoxP3 and suppressed naïve T-cell proliferation, in addition to the previously known CD4+CD25+ Treg cells. These CD8+ Treg cells suppressed naïve T-cell proliferation mainly through a cell contact–dependent mechanism. Importantly, the suppressive function of CD8+ Treg cells could be reversed by human Toll-like receptor 8 (TLR8) signaling.
Conclusion: Our study shows that like CD4+CD25+ Treg cells, CD8+ Foxp3+ Treg cells present in prostate tumor–derived TILs suppress immune responses and that their suppressive function can be regulated by TLR8 ligands, raising the possibility that the manipulation of Treg cell function by TLR8 ligands could improve the efficacy of immunotherapy for prostate cancer patients.
This article has been cited by other articles:
![]() |
I. Sobhani and S. Le Gouvello Critical role for CD8+FoxP3+ regulatory T cells in colon cancer immune response in humans Gut, June 1, 2009; 58(6): 743 - 744. [Full Text] [PDF] |
||||
![]() |
I. Kryczek, R. Liu, G. Wang, K. Wu, X. Shu, W. Szeliga, L. Vatan, E. Finlayson, E. Huang, D. Simeone, et al. FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease Cancer Res., May 1, 2009; 69(9): 3995 - 4000. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Chaput, S Louafi, A Bardier, F Charlotte, J-C Vaillant, F Menegaux, M Rosenzwajg, F Lemoine, D Klatzmann, and J Taieb Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue Gut, April 1, 2009; 58(4): 520 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Siegmund, B. Ruckert, N. Ouaked, S. Burgler, A. Speiser, C. A. Akdis, and C. B. Schmidt-Weber Unique Phenotype of Human Tonsillar and In Vitro-Induced FOXP3+CD8+ T Cells J. Immunol., February 15, 2009; 182(4): 2124 - 2130. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Han, Q. Guo, M. Zhang, Z. Chen, and X. Cao CD69+CD4+CD25- T Cells, a New Subset of Regulatory T Cells, Suppress T Cell Proliferation through Membrane-Bound TGF-{beta}1 J. Immunol., January 1, 2009; 182(1): 111 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Simone, A. Zicca, and D. Saverino The frequency of regulatory CD3+CD8+CD28-CD25+ T lymphocytes in human peripheral blood increases with age J. Leukoc. Biol., December 1, 2008; 84(6): 1454 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bai, E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen From the Cover: Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice PNAS, September 2, 2008; 105(35): 13003 - 13008. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Peng, H. Y. Wang, Y. Miyahara, G. Peng, and R.-F. Wang Tumor-Associated Galectin-3 Modulates the Function of Tumor-Reactive T Cells Cancer Res., September 1, 2008; 68(17): 7228 - 7236. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |